New England
Science Symposium

PURPOSE

The New England Science Symposium (NESS), established in 2002, provides a forum for postdoctoral fellows; medical, dental and graduate students; post-baccalaureates; college and community college students (particularly for African-American, Hispanic/Latino and American Indian/Alaska Native individuals) to share their biomedical and health-related research activities through oral or poster presentations, to engage in discussions related to career development in the sciences, to exchange ideas and to expand their professional networks.

AWARDS

Awards for outstanding oral and poster presentations in various disciplines and categories are: Ruth and William Silen, M.D. Awards, Dana-Farber/Harvard Cancer Center Awards, Postdoctoral Awards sponsored by Vertex, Beth Israel Deaconess Medical Center Department of Neonatology Award, TACS BIO Stem Cell and Regenerative Medicine Award, American Cancer Society Awards, and Predicine Translational Research Award.

For description of the awards,please click here.

For 2023 award winners, please click here

Harvard Medical School
Minority Faculty Development Program (MFDP)

The Minority Faculty Development Program (est.1990), a component of DICP, sponsors programs for the development of Harvard Medical School faculty and trainees, with an emphasis on mentoring and leadership, as well as programs that are designed to reach out to the pre-college, college, graduate and postdoctoral populations with the goal of bringing outstanding students from groups underrepresented in medicine into the biomedical science pipeline.

Biomedical Science Careers Program (BSCP)

BSCP was founded in 1991 by MFDP in collaboration with the Massachusetts Medical Society and the New England Board of Higher Education to identify, inform, support and provide mentoring for academically outstanding minority students and fellows ranging from high school to postdoctoral level.

SUPPORTER

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Contacts

For more information please contact:
 

Pinar Kilicci-Kret
Program Manager
Biomedical Sciences Careers Program
pinar_kilicci-kret@hms.harvard.edu

Hollie Borek DeSilva
Executive Director
Biomedical Science Careers Program
hollie_desilva@hms.harvard.edu